Research programme: G-protein-coupled bile acid receptor-1 agonists - Ardelyx

Drug Profile

Research programme: G-protein-coupled bile acid receptor-1 agonists - Ardelyx

Alternative Names: Gpbar1 Agonists - Ardelyx; RDX 009; RDX 98940; TGR5 Agonists - Ardelyx

Latest Information Update: 12 May 2016

Price : $50

At a glance

  • Originator Ardelyx
  • Class Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diarrhoea; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Short bowel syndrome
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 09 May 2016 Ardelyx plans to file an IND application for RDX 98940 to the US FDA
  • 10 Sep 2015 Ardelyx plans to file an IND application for RDX 009 with the US FDA
  • 09 Sep 2015 Preclinical trials in Diarrhoea, Inflammatory bowel disease, Non-alcoholic steatohepatitis, Short bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top